Basic info.

Alias: Arimidex

CAS No:   120511-73-1

MF: C17H19N5

MW: 293.37

Purity: 98%min

Appearance: White crystalline powder.

Usage: An aromatase inhibitor. Used as an antineoplastic raw materials.

Description:

Arimidex is the aromatase inhibitor of choice. Arimidex's mechanism of action - blocking conversion of aromatizable steroids to estrogen - is in contrast to the mechanism of action of anti-estrogens such as clomiphene (Clomid) or (Nolvadex), which block estrogen receptors in some tissues, and activate estrogen receptors in others.

Anastrozoles is an aromatase-inhibiting drug approved for treatment of breast cancer after surgery, as well as for metastasis in both pre and postmenopausal women. The severity of breast cancer is increased by estrogen, as sexhormones cause hyperplasia, and differentiation at estrogen receptor sites. Anastrozoles works by inhibiting the synthesis of estrogen.

The trial suggested that anastrozoles is the preferred medical therapy for Postmenopausal women with localized breast cancer that is estrogen receptor (ER) positive.

Application:

The drug is appropriately used when using substantial amounts of aromatizing steroids, or when one is prone to gynecomastia and using moderate amounts of such steroids. 

Arimidex does not have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen blockade, much moreso than Cytadren. 

It is possible to reduce estrogen too much with Arimidex, and for this reason blood tests, or less preferably salivary tests, should be taken after the first week of use to determine if the dosing is correct.

Potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 aromatase enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast cancer cell growth factors. 

Treatment of breast cancer, especially for those with hormone relapse after adjuvant therapy after menopause for women with advanced breast cancer.